A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of AC176 in Chinese Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Latest Information Update: 01 Feb 2024
At a glance
- Drugs AC 0176 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Accutar Biotechnology
Most Recent Events
- 23 Jan 2024 Status changed from active, no longer recruiting to discontinued (Subject benefit-risk ratio changes, sponsor decides to voluntarily terminate study ).
- 24 Oct 2023 Status changed from recruiting to active, no longer recruiting.
- 28 Feb 2023 New source identified & integrated (ClinicalTrials.gov: NCT05673109)